Motus GI (MOTS) 10-Q 14 May 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 07, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-38389
Entity Registrant Name	Motus GI Holdings, Inc.
Entity Central Index Key	0001686850
Entity Tax Identification Number	81-4042793
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1301 East Broward Boulevard
Entity Address, Address Line Two	3rd Floor
Entity Address, City or Town	Ft. Lauderdale
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33301
City Area Code	(954)
Local Phone Number	541 8000
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	MOTS
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,768,876

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 4,944	$ 4,958
Accounts receivable	81	76
Inventory, current	228	245
Prepaid expenses and other current assets	497	478
Total current assets	5,750	5,757
Fixed assets, net	897	992
Inventory, non-current	251	251
Right-of-use assets	155	210
Other non-current assets	13	13
Total assets	7,066	7,223
Current liabilities:
Accounts payable and accrued expenses	1,495	1,842
Operating lease liabilities - current	116	169
Other current liabilities	66	226
Current portion of long-term debt, net of unamortized debt discount of $91 and $108, respectively	1,632	1,033
Total current liabilities	3,309	3,270
Long-term debt, net of unamortized debt discount of $5 and $16, respectively	669	1,239
Operating lease liabilities - non-current	21	27
Total liabilities	3,999	4,536
Commitments and contingent liabilities (Note 9)
Shareholders’ equity
Common stock $0.0001 par value; 115,000,000 shares authorized; 5,210,876 and 1,547,042 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	1
Additional paid-in capital	159,397	156,905
Accumulated deficit	(156,331)	(154,218)
Total shareholders’ equity	3,067	2,687
Total liabilities and shareholders’ equity	$ 7,066	$ 7,223

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Debt instrument, unamortized discount	$ 91	$ 108
Debt instrument, unamortized discount, non-current	$ 5	$ 16
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	115,000,000	115,000,000
Common stock, shares issued	5,210,876	1,547,042
Common stock, shares outstanding	5,210,876	1,547,042

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 64	$ 56
Operating expenses:
Cost of revenue - sales	12	9
Cost of revenue - impairment of inventory		165
Research and development	455	1,454
Sales and marketing	151	842
General and administrative	1,472	1,945
Total costs and expenses	2,090	4,415
Loss from operations	(2,026)	(4,359)
Gain on change in estimated fair value of contingent royalty obligation		220
Finance expense, net	(80)	(239)
Foreign currency loss	(7)	(8)
Net loss	(2,113)	(4,386)
Deemed dividends from warrant issuance	(5,508)
Net loss attributable to common shareholders	$ (7,621)	$ (4,386)
Basic and diluted loss per common share:
Net loss - Basic	$ (0.25)	$ (13.81)
Net loss - Diluted	(0.25)	(13.81)
Basic loss per common share	(0.88)	(13.81)
Diluted loss per common share	$ (0.88)	$ (13.81)
Weighted average number of common shares outstanding, basic	8,613,204	317,547
Weighted average number of common shares outstanding, diluted	8,613,204	317,547

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' (Deficiency) Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022		$ 144,328	$ (141,351)	$ 2,977
Balance, shares at Dec. 31, 2022	310,494
Share based compensation		222		222
Net loss			(4,386)	(4,386)
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs of $19		102		102
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs, shares	7,942
Balance at Mar. 31, 2023		144,652	(145,737)	(1,085)
Balance, shares at Mar. 31, 2023	318,436
Balance at Dec. 31, 2023		156,905	(154,218)	2,687
Balance, shares at Dec. 31, 2023	1,547,042
Issuance of warrants upon settlement of placement agent warrant obligation		154		154
Issuance of common shares upon exercise of warrants net of financing fees of $504	$ 1	2,267		2,268
Issuance of common shares upon exercise of warrants net of financing fees, shares	3,663,834
Share based compensation		71		71
Net loss			(2,113)	(2,113)
Balance at Mar. 31, 2024	$ 1	$ 159,397	$ (156,331)	$ 3,067
Balance, shares at Mar. 31, 2024	5,210,876

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Shareholders' (Deficiency) Equity (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Stockholders' Equity [Abstract]
Financing fees	$ 504
Net of issuance costs		$ 19

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,113)	$ (4,386)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	95	117
Amortization of debt issuance costs	30	62
Gain on change in estimated fair value of contingent royalty obligation		(220)
Share based compensation	71	222
Impairment of inventory		165
Amortization on operating lease right-of-use asset	55	73
Changes in operating assets and liabilities:
Accounts receivable	(5)	7
Inventory	17	22
Prepaid expenses and other current assets	(19)	(312)
Accounts payable and accrued expenses	(88)	(472)
Operating lease liabilities - current and non-current	(60)	(74)
Other current and non-current liabilities	(6)	(6)
Net cash used in operating activities	(2,023)	(4,802)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets		(39)
Net cash used in investing activities		(39)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common shares		121
Proceeds from exercise of warrants	2,712
Repayment of debt		(655)
Payment of debt issuance costs and financing fees	(328)
Equity financing fees	(375)	(19)
Net cash provided by (used in) financing activities	2,009	(553)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(14)	(5,394)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	4,958	14,042
CASH AND CASH EQUIVALENTS AT END OF PERIOD	4,944	8,648
CASH PAID FOR:
Interest	81	246
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES:
Issuance of warrants upon settlement of placement agent warrant obligation	154
Non-cash issuance costs from warrant issuance	60
Reclassification of inventory to fixed assets		14
Financing fees incurred but unpaid at period end	69
Right-of-use asset obtained in exchange for lease obligation		$ 35

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (2,113)	$ (4,386)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual [Table]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Description of Business

Description of Business	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1 – Description of Business Motus GI Holdings, Inc. (the “Company”) was incorporated in Delaware, U.S.A. in September 2016. The Company and its subsidiaries, Motus GI Technologies, Ltd. and Motus GI, LLC, are collectively referred to as “Motus GI” or the “Company”. The Company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the “FDA”) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (“GI”) endoscopy procedures. The Pure-Vu System has received a CE Mark in the EU for use in colonoscopy. The Pure-Vu System integrates with standard and slim colonoscopes, as well as gastroscopes, to improve visualization during colonoscopy and upper GI procedures while preserving established procedural workflow and techniques. Through irrigation and evacuation of debris, the Pure-Vu System is designed to improve visualization to provide better-quality exams and avoid delayed or canceled procedures.. The Company received 510(k) clearance in October 2023 from the FDA for the Pure-Vu EVS System for use in the upper GI tract and Gen 4 Colon and has commenced limited market introduction of these products in over the last few months. Both devices leverage the same workstation and feature key enhancements such as a larger and more powerful suction channel, more efficient irrigation jets, a smaller profile distal tip that offers enhanced flexibility during insertion, enhanced navigation and a much easier bed side set up. The Company does not expect to generate significant revenue from product sales until it further expands its commercialization efforts, which is subject to significant uncertainty.

Basis of Presentation and Going

Basis of Presentation and Going Concern Uncertainty	3 Months Ended
	Mar. 31, 2024
Basis Of Presentation And Going Concern Uncertainty
Basis of Presentation and Going Concern Uncertainty	Note 2 – Basis of Presentation and Going Concern Uncertainty The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the 2023 10-K filed with the SEC on March 18, 2024. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information, the instructions for Form 10-Q and the rules and regulations of the SEC. Accordingly, since they are interim statements, the accompanying condensed consolidated financial statements do not include all of the information and notes required by GAAP for annual financial statements, but reflect all adjustments consisting of normal, recurring adjustments, that are necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of the results that may be expected for any future periods. The December 31, 2023 balance sheet information was derived from the audited financial statements as of that date. The Company has generated limited revenues to date from the sale of products. The Company has never been profitable and has incurred significant net losses each year since its inception, including a loss of $ 2.1 2.0 4.9 156.3 We are exploring a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System. If a strategic transaction is not completed, or if additional financing is not available, we may not be able to service our outstanding indebtedness and our payables and may have to file for bankruptcy protection or pursue a dissolution of the Company and liquidation of all of our remaining assets. In such an event, the amount of cash available for distribution to our stockholders, if any, will depend heavily on the timing of such decision, as with the passage of time the amount of cash available for distribution will be reduced as we continue to fund our operations and service our outstanding indebtedness. We cannot provide assurance as to the amount of cash that will be available to distribute to stockholders, if any, after paying our debts and other obligations and setting aside funds for reserves, nor as to the timing of any such distribution, if any. Such conditions raise substantial doubt about the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments that might result from the outcome for this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Significant Accounting Policies The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2024 are consistent with those discussed in Note 3 to the consolidated financial statements in the Company’s 2023 Annual Report on Form 10-K. There have been no material changes to the Company’s significant accounting policies during the three months ended March 31, 2024. Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and include the accounts of the Company and its wholly owned subsidiaries, Motus Ltd., an Israel corporation, which has operations in Tirat Carmel, Israel, and Motus Inc., a Delaware corporation, which has operations in the U.S. All inter-company accounts and transactions have been eliminated in consolidation. Use of estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Reverse Stock Split On November 2, 2023, the Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-15 (the “2023 Reverse Stock Split”). No fractional shares were issued in connection with the 2023 Reverse Stock Split. Stockholders who would otherwise be entitled to a fractional share of common stock instead receive a proportional cash payment. Basic and diluted net loss per share Basic net loss per share is calculated by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding during the applicable period. Diluted net loss per share is calculated by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding for the applicable period, including any potentially dilutive securities such as stock options, unvested restricted stock, warrants, and other convertible instruments unless the result of inclusion would be antidilutive. The dilutive effect of restricted stock units subject to vesting and other share-based payment awards is calculated using the “treasury stock method,” which assumes that the “proceeds” from the exercise of these instruments are used to purchase common shares at the average market price for the period. The dilutive effect of convertible securities is calculated using the “if-converted method.” Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented. The shares of common stock issuable under certain outstanding pre-funded warrants and shares of common stock held by the Company in abeyance are considered outstanding for the purposes of computing earnings per share, as these shares may be issued for little or no consideration, are fully vested, and are exercisable after the original issuance date. The 2,432,705 in connection with the February 2024 Warrant Exercise 1,980,000 The Company recorded a deemed dividend of $ 5,508 The deemed dividend is added to the net loss in determining the net loss available to common stockholders. Income taxes The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of March 31, 2024 and 2023, the Company had a full valuation allowance against its deferred tax assets. For the three months ended March 31, 2024 and 2023, the Company recorded zero New Accounting Pronouncements- Recently Adopted In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This guidance simplifies the accounting for convertible instruments primarily by eliminating the existing cash conversion and beneficial conversion models within Subtopic 470-20, which will result in fewer embedded conversion options being accounted for separately from the debt host. The guidance also amends and simplifies the calculation of earnings per share relating to convertible instruments. The Company adopted this ASU on January 1, 2024. The adoption of this ASU did not result in a material impact to the consolidated financial statements and disclosures. Accounting Pronouncements- Not Yet Adopted In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting In November 2023, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in ASU 2023-07 improve reportable segment disclosure requirements through enhanced disclosures. These new requirements include: disclosure of significant segment expenses regularly provided to the CODM, the title and position of the CODM, and the extension of certain annual disclosures to interim periods, permitting the disclosure of multiple measures of segment profit or loss, provided that certain criteria are met. The standard also clarifies that entities with a single reportable segment are subject to new and existing segment reporting requirements. The standard will be effective for annual periods in fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. Entities must adopt the changes to the segment reporting guidance on a retrospective basis. The Company is continuing to assess the potential impacts of the amendments, and it does not expect this pronouncement to have a material effect on its condensed consolidated financial statements, other than the required changes to the segment disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 requires entities to disclose additional information in specified categories in the reconciliation of the effective tax rate to the statutory rate for federal, state, and foreign income taxes. ASU 2023-09 also requires greater detail about individual reconciling items in the rate reconciliation to the extent the impact of those items exceeds a specified threshold and eliminates certain existing disclosures. In addition to new disclosures associated with the rate reconciliation, the standard requires information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. The standard will be effective for annual periods in fiscal years beginning after December 15, 2024, and for interim periods for fiscal years beginning after December 15, 2025. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively, and early adoption is permitted. The Company is continuing to assess the potential impacts of the standard, and it does not expect this pronouncement to have a material effect on its condensed financial statements, other than the required changes to the income tax disclosures.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4 – Fair Value Measurements Financial instruments with carrying values approximating fair value include cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses, and certain other current liabilities, due to their short-term nature. Debt instruments are measured at amortized cost on the Company’s condensed consolidated balance sheets. If measured at fair value in the financial statements, these instruments would be classified as Level 2 in the fair value hierarchy.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
Inventory	Note 5 – Inventory Inventory is stated at lower of cost or net realizable value using the weighted average cost method and is evaluated at least annually for impairment. Write-downs for potentially obsolete or excess inventory are made based on management’s analysis of inventory levels, historical obsolescence and future sales forecasts. For the three months ended March 31, 2024 and 2023, an inventory impairment of $ 0 165 Inventory at March 31, 2024 and December 31, 2023 consisted of the following: Schedule of Inventory March 31, 2024 December 31, 2023 Raw materials $ 451 $ 487 Work-in-process - 196 Finished goods 756 541 Inventory reserve (728 ) (728 ) Inventory, net $ 479 $ 496 Less: Inventory, current $ 228 $ 245 Inventory, non-current $ 251 $ 251

Fixed assets, net

Fixed assets, net	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Fixed assets, net	Note 6 – Fixed assets, net Fixed assets, summarized by major category, consist of the following at March 31, 2024 and December 31, 2023: Schedule of Fixed Assets Net March 31, 2024 December 31, 2023 Office equipment $ 171 $ 171 Computers and software 321 321 Machinery 1,155 1,155 Lab and medical equipment 1,489 1,489 Leasehold improvements 200 200 Total 3,336 3,336 Less: accumulated depreciation and amortization (2,439 ) (2,344 ) Fixed assets, net $ 897 $ 992 Depreciation and amortization expense for the three months ended March 31, 2024 and 2023 was $ 95 117

Leases

Leases	3 Months Ended
	Mar. 31, 2024
Leases
Leases	Note 7 – Leases The Company leases offices in Fort Lauderdale, Florida and Israel which expire in November 2024 and December 2024, respectively. The Company also leases vehicles under operating leases that expire at various dates through 2026 The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows: Schedule of Lease Cost and Supplemental Balance Sheet Information Three Months Ended Three Months Ended March 31, 2024 March 31, 2023 Lease Cost Operating lease (income) cost, net of related party license fee $ (10 ) $ 16 Variable lease cost 41 25 Short-term lease cost 47 40 Total lease cost $ 78 $ 81 As of As of March 31, 2024 December 31, 2023 Assets Operating lease, right-of-use- asset $ 155 $ 210 Liabilities Current Operating lease liabilities $ 116 $ 169 Non-current Operating lease liabilities, net of current portion 21 27 Total lease liabilities $ 137 $ 196 Other information: Weighted average remaining lease term - operating leases 1.05 1.18 Weighted-average discount rate - operating leases 7.24 % 7.3 % The Company’s lease expense is included in general and administrative expenses which is net of the related party license fee of $ 67 49

Convertible Note and Long-Term

Convertible Note and Long-Term Debt	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Convertible Note and Long-Term Debt	Note 8 – Convertible Note and Long-Term Debt On July 16, 2021 (the “Effective Date”), the Company entered into a loan facility (the “Kreos Loan Agreement”) with Kreos Capital VI (Expert Fund) LP (the “Lender”). Under the Kreos Loan Agreement, the Lender will provide the Company with access to term loans in an aggregate principal amount of up to $ 12,000 4,000 5,000 3,000 The Convertible Note and Tranche B were funded on the Effective Date. As of December 31, 2021, t 3,000 The Convertible Note was settled in December 2023, concurrent with the Company closing on a public offering of equity securities, in exchange for shares of the Company’s common stock or pre-funded warrants to purchase the Company’s common stock and additional warrants to purchase the Company’s common stock. The Company has made aggregate payments on the Long-term Debt of $ 5,743 5,681 62 1.75 The Tranche B loan initially required interest only monthly payments commencing on the Effective Date until September 30, 2022, and, thereafter, thirty-three monthly payments of principal and interest accrued thereon until June 1, 2025, as well as the payment of an end of loan payment of 1.75 , as well as the payment of an end of loan payment of 1.75 As part of the First Amendment to the Kreos Loan Agreement, the Company will make interest only monthly payments for six months, at the stated 9.5 June 1, 2025 Upon the initial funding of the Tranche B and C Loans, the Lender retained the final payments of principal and interest due on June 1, 2025, totaling $ 274 , of which $ 197 remains unapplied and was recorded in prepaid expense and other current assets at March 31, 2024. For the three months ended March 31, 2024 and 2023, interest expense for the Loan was as follows: Schedule of Interest Expense for Loan 2024 2023 Three Months March 31, 2024 2023 Contractual interest expense $ 55 $ 246 Amortization of debt issuance costs 30 62 Total interest expense $ 85 $ 308 Future principal payments under the Long-term Debt as of March 31, 2024 are as follows: Schedule of Future Principal Payments of Convertible Note Amount 2024 $ 1,723 2025 596 Total future principal payments 2,319 End of loan payments 78 Less unamortized debt issuance costs of current portion of long-term debt (91 ) Less unamortized debt issuance costs of non-current portion long-term debt (5 ) Total balance $ 2,301 Less long-term debt, current $ 1,632 Long-term debt, net of current portion $ 669

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 – Commitments and Contingencies The Company has entered into and expects to enter into from time to time in the future, license agreements, strategic alliance agreements, assignment agreements, research service agreements, and similar agreements related to the advancement of its research and development efforts. Significant agreements are described in detail in the Company’s 2023 Form 10-K. While specific amounts will differ from quarter to quarter, the Company believes its overall activities regarding these agreements are materially consistent with those described in the 2023 Form 10-K. In addition to the specific agreements described in the 2023 Form 10-K, the Company has entered into, and will in the future enter into, other research and service provider agreements for the advancement of its research and development efforts. The Company expects to pay additional amounts in future periods in connection with existing and future research and service provider agreements.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Note 10 – Related Party Transactions Shared Space Agreement In January 2020, the Company entered into a license agreement (the “Shared Space Agreement”) with Orchestra BioMed, Inc. (OBIO), formerly a greater than 5 % holder of the Company’s common stock. Pursuant to the Shared Space Agreement, the Company granted a license to OBIO for the use of portions of the office space not being used by the Company in the Company’s leased facility in Fort Lauderdale, Florida (the “Premises”), and a proportionate share of common areas of such Premises, which previously covered approximately 35% of the Premises and was to expand incrementally to approximately 60 to 70% of the Premises by September 2024. In May 2022, the Company entered into an amendment to the Shared Space Agreement. Pursuant to the amendment, the area covered by the Shared Space Agreement was expanded to 95% of the premises and the aggregate license fees will generally range from approximately $ 212 to approximately $ 270 in any given calendar year during the term of the Shared Space Agreement until the termination of the lease in November 2024. During the three months ended March 31, 2024 and 2023, the Company recorded a license fee of $ 67 and $ 49 , respectively, in relation to the Shared Space Agreement. This amount is netted with rent expense in general and administrative expenses. Extinguishment of Royalty Obligation As noted in Note 4, the Company extinguished its royalty obligation in exchange for equity interests during Q3 2023. OBIO held the majority of the Royalty Payment Rights Certificates, and as such approved the Amendment Agreement and the settlement exchange. OBIO received 46,768 The change in the fair value of the contingent royalty obligation during the three months ended March 31, 2023 was a decrease of $ 220

Share-based compensation, warra

Share-based compensation, warrants and common stock issuances	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Share-based compensation, warrants and common stock issuances	Note 11 – Share-based compensation, warrants and common stock issuances The following table sets forth total non-cash share-based compensation for the issuance of common stock, options to purchase common stock, and restricted stock unit awards by operating statement classification for the three months ended March 31, 2024 and 2023: Schedule of Stock-based Compensation 2024 2023 Three Months ended March 31, 2024 2023 Research and development $ 23 $ 59 Sales and marketing 6 1 General and administrative 42 162 Total $ 71 $ 222 As of March 31, 2024, unamortized share-based compensation for stock options was $ 313 1.13 Stock option and warrant activity A summary of the Company’s stock option and warrant activity is as follows: Schedule of Stock Option and Warrants Options Warrants Shares Underlying Options Weighted Average Exercise Price Shares Underlying Warrants Weighted Average Exercise Price Outstanding at December 31, 2023 60,170 $ 171.23 17,455,312 $ 1.99 Awarded - $ - 4,697,085 $ 0.79 Exercised - $ - (5,643,863 ) $ 0.48 Expired - $ - (1,132 ) $ 525.0 Outstanding at March 31, 2024 60,170 $ 171.23 16,507,402 $ 0.96 Exercisable at March 31, 2024 21,297 $ 462.93 16,507,402 $ 0.96 As of March 31, 2024 and December 31, 2023, there were 1,009 125.42 As of March 31, 2024, unamortized stock compensation for restricted stock units was $ 14 0.54 As of March 31, 2024, in connection with the February 2024 Warrant Exercise (as defined herein) 1,980,000 Private Placement Offering On May 17, 2023, the Company entered into a securities purchase agreement with an accredited investor pursuant to which it agreed to issue and sell in a private placement an aggregate of (i) 35,000 241,134 276,134 12.675 12.674 3.0 0.5 0.2 10.80 0.0001 In addition, pursuant to the terms of the offering, the Company issued the placement agent, H.C. Wainwright & Co., LLC., warrants to purchase up to 13,806 15.845 December 2023 Public Offering and Convertible Note Exchange On December 18, 2023, the Company entered into a securities purchase agreement with certain purchasers pursuant to which it agreed to issue and sell, in a public offering (the “Public Offering”), an aggregate of (i) 520,000 2,813,334 3,333,334 3,333,334 1.50 1.4999 3.9 1.1 0.1 The Public Offering Pre-Funded Warrants are exercisable until exercised in full at an exercise price of $ 0.0001 1.50 1.50 4.99 9.99 As part of the Public Offering, the Company entered into a placement agency agreement with Alliance Global Partners (“A.G.P.”), pursuant to which A.G.P. agreed to act as exclusive placement agent for the issuance and sale of the securities in the Public Offering. In exchange for these services, the Company paid A.G.P. an aggregate cash fee of $ 0.4 0.6 In connection with the completion of the Public Offering, the Company was also obligated to issue H.C. Wainwright & Co., LLC. warrants to purchase an aggregate of 150,417 1.875 154 As discussed in Note 8, the Company issued (i) 54,461 shares of Common Stock, (ii) the Private Pre-Funded Warrants to purchase up to 2,612,205 shares of common stock, (iii) the Series A Private Warrants to purchase up to 2,666,666 shares of common stock and (iv) the Series B Private Warrants to purchase up to 2,666,666 shares of common stock upon the exchange and cancellation of the $ 4,000 1.50 0.0001 4.99 9.99 February 2024 Warrant Exchange Agreement On February 21, 2024, the Company and an investor who had previously participated in the May 2023 Private Placement Offering and the December 2023 Public Offering entered into an agreement for the immediate exercise of certain outstanding warrants, the issuance of new warrants and the modification of other previously issued and outstanding warrants (the “February 2024 Warrant Exercise”). The February 2024 Warrant Exercise closed on February 26, 2024. Under the terms of the February 2024 Warrant Exercise, the investor agreed to immediately exercise 2,933,334 0.925 1.50 2,200,000 0.74 2,200,001 0.74 0.74 All of the previously issued warrants impacted by the February 2024 Warrant Exercise had been determined to be equity-classified by the Company. In addition, the Company determined that the newly issued Series B-1 and Series B-2 Warrants also met the requirements for equity classification. Given the terms of the February 2024 Warrant Exercise, the Company determined that the investor had agreed to exercise the Series B Common Warrants under an inducement offer, which included the reduction in exercise price of the Series B Common Warrants as well as the issuance of the Series B-1 and Series B-2 Warrants. The Company measured the additional value provided to the investor under such actions based on the reduction in exercise price (reflecting the increased intrinsic value to the investor) and the estimated fair value of the newly issued Series B-1 and Series B-2 Warrants (using a Black-Scholes model) to be approximately $ 5,027 481 5,508 In connection with the completion of the February 2024 Warrant Exercise, the Company was also obligated to issue H.C. Wainwright & Co., LLC. warrants to purchase an aggregate of 146,667 1.1563 0.1

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 12 – Subsequent Events On May 12, 2024, Ravit Ram, our Chief Financial Officer, submitted a notice of resignation to the Company effective May 30, 2024. As previously disclosed, on March 10, 2024, the Company’s board of directors reserved a total of $ 900,000 for potential cash bonus payments to the Company’s employees, contingent upon the achievement of a strategic transaction, the criteria of which to be determined by the board of directors, during the year ending December 31, 2024. On May 13, 2024, the board of directors approved the allocation of the total $ 900,000 , in the event of a strategic transaction, with $ 288,000 100,000 allocated to Elad Amor, the Company’s Chief Accounting Officer, and $ 512,000 Effective May 13, 2024, our common stock was listed for trading on the OTCQB under our current ticker symbol “MOTS.”

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of presentation and principles of consolidation	Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and include the accounts of the Company and its wholly owned subsidiaries, Motus Ltd., an Israel corporation, which has operations in Tirat Carmel, Israel, and Motus Inc., a Delaware corporation, which has operations in the U.S. All inter-company accounts and transactions have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Reverse Stock Split	Reverse Stock Split On November 2, 2023, the Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-15 (the “2023 Reverse Stock Split”). No fractional shares were issued in connection with the 2023 Reverse Stock Split. Stockholders who would otherwise be entitled to a fractional share of common stock instead receive a proportional cash payment.
Basic and diluted net loss per share	Basic and diluted net loss per share Basic net loss per share is calculated by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding during the applicable period. Diluted net loss per share is calculated by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding for the applicable period, including any potentially dilutive securities such as stock options, unvested restricted stock, warrants, and other convertible instruments unless the result of inclusion would be antidilutive. The dilutive effect of restricted stock units subject to vesting and other share-based payment awards is calculated using the “treasury stock method,” which assumes that the “proceeds” from the exercise of these instruments are used to purchase common shares at the average market price for the period. The dilutive effect of convertible securities is calculated using the “if-converted method.” Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented. The shares of common stock issuable under certain outstanding pre-funded warrants and shares of common stock held by the Company in abeyance are considered outstanding for the purposes of computing earnings per share, as these shares may be issued for little or no consideration, are fully vested, and are exercisable after the original issuance date. The 2,432,705 in connection with the February 2024 Warrant Exercise 1,980,000 The Company recorded a deemed dividend of $ 5,508 The deemed dividend is added to the net loss in determining the net loss available to common stockholders.
Income taxes	Income taxes The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of March 31, 2024 and 2023, the Company had a full valuation allowance against its deferred tax assets. For the three months ended March 31, 2024 and 2023, the Company recorded zero
New Accounting Pronouncements- Recently Adopted	New Accounting Pronouncements- Recently Adopted In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This guidance simplifies the accounting for convertible instruments primarily by eliminating the existing cash conversion and beneficial conversion models within Subtopic 470-20, which will result in fewer embedded conversion options being accounted for separately from the debt host. The guidance also amends and simplifies the calculation of earnings per share relating to convertible instruments. The Company adopted this ASU on January 1, 2024. The adoption of this ASU did not result in a material impact to the consolidated financial statements and disclosures.
Accounting Pronouncements- Not Yet Adopted	Accounting Pronouncements- Not Yet Adopted In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting In November 2023, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in ASU 2023-07 improve reportable segment disclosure requirements through enhanced disclosures. These new requirements include: disclosure of significant segment expenses regularly provided to the CODM, the title and position of the CODM, and the extension of certain annual disclosures to interim periods, permitting the disclosure of multiple measures of segment profit or loss, provided that certain criteria are met. The standard also clarifies that entities with a single reportable segment are subject to new and existing segment reporting requirements. The standard will be effective for annual periods in fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. Entities must adopt the changes to the segment reporting guidance on a retrospective basis. The Company is continuing to assess the potential impacts of the amendments, and it does not expect this pronouncement to have a material effect on its condensed consolidated financial statements, other than the required changes to the segment disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 requires entities to disclose additional information in specified categories in the reconciliation of the effective tax rate to the statutory rate for federal, state, and foreign income taxes. ASU 2023-09 also requires greater detail about individual reconciling items in the rate reconciliation to the extent the impact of those items exceeds a specified threshold and eliminates certain existing disclosures. In addition to new disclosures associated with the rate reconciliation, the standard requires information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. The standard will be effective for annual periods in fiscal years beginning after December 15, 2024, and for interim periods for fiscal years beginning after December 15, 2025. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively, and early adoption is permitted. The Company is continuing to assess the potential impacts of the standard, and it does not expect this pronouncement to have a material effect on its condensed financial statements, other than the required changes to the income tax disclosures.

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory at March 31, 2024 and December 31, 2023 consisted of the following: Schedule of Inventory March 31, 2024 December 31, 2023 Raw materials $ 451 $ 487 Work-in-process - 196 Finished goods 756 541 Inventory reserve (728 ) (728 ) Inventory, net $ 479 $ 496 Less: Inventory, current $ 228 $ 245 Inventory, non-current $ 251 $ 251

Fixed assets, net (Tables)

Fixed assets, net (Tables)	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets Net	Fixed assets, summarized by major category, consist of the following at March 31, 2024 and December 31, 2023: Schedule of Fixed Assets Net March 31, 2024 December 31, 2023 Office equipment $ 171 $ 171 Computers and software 321 321 Machinery 1,155 1,155 Lab and medical equipment 1,489 1,489 Leasehold improvements 200 200 Total 3,336 3,336 Less: accumulated depreciation and amortization (2,439 ) (2,344 ) Fixed assets, net $ 897 $ 992

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2024
Leases
Schedule of Lease Cost and Supplemental Balance Sheet Information	The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows: Schedule of Lease Cost and Supplemental Balance Sheet Information Three Months Ended Three Months Ended March 31, 2024 March 31, 2023 Lease Cost Operating lease (income) cost, net of related party license fee $ (10 ) $ 16 Variable lease cost 41 25 Short-term lease cost 47 40 Total lease cost $ 78 $ 81 As of As of March 31, 2024 December 31, 2023 Assets Operating lease, right-of-use- asset $ 155 $ 210 Liabilities Current Operating lease liabilities $ 116 $ 169 Non-current Operating lease liabilities, net of current portion 21 27 Total lease liabilities $ 137 $ 196 Other information: Weighted average remaining lease term - operating leases 1.05 1.18 Weighted-average discount rate - operating leases 7.24 % 7.3 %

Convertible Note and Long-Ter_2

Convertible Note and Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Schedule of Interest Expense for Loan	For the three months ended March 31, 2024 and 2023, interest expense for the Loan was as follows: Schedule of Interest Expense for Loan 2024 2023 Three Months March 31, 2024 2023 Contractual interest expense $ 55 $ 246 Amortization of debt issuance costs 30 62 Total interest expense $ 85 $ 308
Schedule of Future Principal Payments of Convertible Note	Future principal payments under the Long-term Debt as of March 31, 2024 are as follows: Schedule of Future Principal Payments of Convertible Note Amount 2024 $ 1,723 2025 596 Total future principal payments 2,319 End of loan payments 78 Less unamortized debt issuance costs of current portion of long-term debt (91 ) Less unamortized debt issuance costs of non-current portion long-term debt (5 ) Total balance $ 2,301 Less long-term debt, current $ 1,632 Long-term debt, net of current portion $ 669

Share-based compensation, war_2

Share-based compensation, warrants and common stock issuances (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation	The following table sets forth total non-cash share-based compensation for the issuance of common stock, options to purchase common stock, and restricted stock unit awards by operating statement classification for the three months ended March 31, 2024 and 2023: Schedule of Stock-based Compensation 2024 2023 Three Months ended March 31, 2024 2023 Research and development $ 23 $ 59 Sales and marketing 6 1 General and administrative 42 162 Total $ 71 $ 222
Schedule of Stock Option and Warrants	A summary of the Company’s stock option and warrant activity is as follows: Schedule of Stock Option and Warrants Options Warrants Shares Underlying Options Weighted Average Exercise Price Shares Underlying Warrants Weighted Average Exercise Price Outstanding at December 31, 2023 60,170 $ 171.23 17,455,312 $ 1.99 Awarded - $ - 4,697,085 $ 0.79 Exercised - $ - (5,643,863 ) $ 0.48 Expired - $ - (1,132 ) $ 525.0 Outstanding at March 31, 2024 60,170 $ 171.23 16,507,402 $ 0.96 Exercisable at March 31, 2024 21,297 $ 462.93 16,507,402 $ 0.96

Basis of Presentation and Goi_2

Basis of Presentation and Going Concern Uncertainty (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Basis Of Presentation And Going Concern Uncertainty
Net loss	$ 2,113	$ 4,386
Net cash used in operating activities	2,023	$ 4,802
Cash and cash equivalents	4,944		$ 4,958
Accumulated deficit	$ 156,331		$ 154,218

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)		3 Months Ended
	Nov. 02, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	May 17, 2023
Reverse stock split	On November 2, 2023, the Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-15 (the “2023 Reverse Stock Split”).
Common stock, shares issued		5,210,876		1,547,042	35,000
Deemed dividends from warrant issuance		$ 5,508,000
Income tax expense		$ 0	$ 0
Prefunded Warrant [Member]
Common stock, shares issued		2,432,705
Common Stock [Member]
Common stock, shares issued		1,980,000			276,134

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 451	$ 487
Work-in-process		196
Finished goods	756	541
Inventory reserve	(728)	(728)
Inventory, net	479	496
Less: Inventory, current	228	245
Inventory, non-current	$ 251	$ 251

Inventory (Details Narrative)

Inventory (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventory impairment	$ 0	$ 165

Schedule of Fixed Assets Net (D

Schedule of Fixed Assets Net (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Total	$ 3,336	$ 3,336
Less: accumulated depreciation and amortization	(2,439)	(2,344)
Fixed assets, net	897	992
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	171	171
Computers And Software [Member]
Property, Plant and Equipment [Line Items]
Total	321	321
Machinery [Member]
Property, Plant and Equipment [Line Items]
Total	1,155	1,155
Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	1,489	1,489
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total	$ 200	$ 200

Fixed assets, net (Details Narr

Fixed assets, net (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 95	$ 117

Schedule of Lease Cost and Supp

Schedule of Lease Cost and Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Leases
Operating lease (income) cost, net of related party license fee	$ (10)	$ 16
Variable lease cost	41	25
Short-term lease cost	47	40
Total lease cost	78	$ 81
Operating Lease, Right-of-Use Asset	155		$ 210
Operating Lease, Liability, Current	116		169
Operating Lease, Liability, Noncurrent	21		27
Operating Lease, Liability	$ 137		$ 196
Weighted average remaining lease term - operating leases	1 year 18 days		1 year 2 months 4 days
Weighted-average discount rate - operating leases	7.24%		7.30%

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Line Items]
License fees	$ 67	$ 49
Office [Member] | Florida and Israel [Member]
Property, Plant and Equipment [Line Items]
Operating lease, description	leases offices in Fort Lauderdale, Florida and Israel which expire in November 2024 and December 2024, respectively. The Company also leases vehicles under operating leases that expire at various dates through 2026

Schedule of Interest Expense fo

Schedule of Interest Expense for Loan (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Debt Disclosure [Abstract]
Contractual interest expense	$ 55	$ 246
Amortization of debt issuance costs	30	62
Total interest expense	$ 85	$ 308

Schedule of Future Principal Pa

Schedule of Future Principal Payments of Convertible Note (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Short-Term Debt [Line Items]
Less long-term debt, current	$ 1,632	$ 1,033
Long-term debt, net of current portion	669	$ 1,239
Convertible Note [Member]
Short-Term Debt [Line Items]
2024	1,723
2025	596
Total future principal payments	2,319
End of loan payments	78
Less unamortized debt issuance costs of current portion of long-term debt	(91)
Less unamortized debt issuance costs of non-current portion long-term debt	(5)
Total balance	2,301
Less long-term debt, current	1,632
Long-term debt, net of current portion	$ 669

Convertible Note and Long-Ter_3

Convertible Note and Long-Term Debt (Details Narrative) - USD ($) $ in Thousands		3 Months Ended		12 Months Ended
	Jul. 16, 2021	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2021	Jan. 01, 2024
Obligation with Joint and Several Liability Arrangement [Line Items]
Payments on long-term debt				$ 5,743
Payment of outstanding principal		$ 5,681
Payments on debt			$ 655	62
Prinicipal of loan payment percentage		1.75%
Tranche C [Member]
Obligation with Joint and Several Liability Arrangement [Line Items]
Debt instrument, periodic payment, principal				$ 3,000
Kreos Loan Agreement [Member]
Obligation with Joint and Several Liability Arrangement [Line Items]
Debt instrument, periodic payment, principal	$ 12,000
Prinicipal of loan payment percentage		1.75%			9.50%
Maturity date		Jun. 01, 2025
Debt Instrument, Periodic Payment		$ 274
Kreos Loan Agreement [Member] | Other Current Assets [Member]
Obligation with Joint and Several Liability Arrangement [Line Items]
Debt instrument, periodic payment, principal		$ 197
Kreos Loan Agreement [Member] | Tranche A [Member]
Obligation with Joint and Several Liability Arrangement [Line Items]
Debt instrument, periodic payment, principal	4,000
Kreos Loan Agreement [Member] | Tranche B [Member]
Obligation with Joint and Several Liability Arrangement [Line Items]
Debt instrument, periodic payment, principal	5,000
Kreos Loan Agreement [Member] | Tranche C [Member]
Obligation with Joint and Several Liability Arrangement [Line Items]
Debt instrument, periodic payment, principal	$ 3,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Jan. 31, 2020
License fee	$ 67	$ 49
Number of shares issued on settlement of royalty payment	46,768
Change in estimated fair value of contingent royalty obligation		$ 220
Minimum [Member]
License fee	212
Maximum [Member]
License fee	$ 270
Shared Space Agreements [Member] | Orchestra Bio Med Inc [Member]
Ownership percentage			5%

Schedule of Stock-based Compens

Schedule of Stock-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 71	$ 222
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	23	59
Selling, General and Administrative Expenses [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	6	1
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 42	$ 162

Schedule of Stock Option and Wa

Schedule of Stock Option and Warrants (Details)	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Warrant [Member]
Offsetting Assets [Line Items]
Shares Underlying Warrants, Outstanding beginning | shares	17,455,312
Weighted Average Exercise Price Warrants, Outstanding beginning | $ / shares	$ 1.99
Shares Underlying Warrants, awarded | shares	4,697,085
Weighted Average Exercise Price Warrants, Awarded | $ / shares	$ 0.79
Shares Underlying Warrants, exercised | shares	(5,643,863)
Weighted Average Exercise Price Warrants, Exercised | $ / shares	$ 0.48
Shares Underlying Warrants, expired | shares	(1,132)
Weighted Average Exercise Price Warrants, Expired | $ / shares	$ 525
Shares Underlying Warrants, outstanding ending | shares	16,507,402
Weighted Average Exercise Price Warrants, Outstanding Ending | $ / shares	$ 0.96
Shares Underlying Warrants, exercisable | shares	16,507,402
Weighted Average Exercise Price Warrants, Exercisable | $ / shares	$ 0.96
Equity Option [Member]
Offsetting Assets [Line Items]
Shares Underlying Options, Outstanding Beginning | shares	60,170
Weighted Average Exercise Price, Outstanding Beginning | $ / shares	$ 171.23
Shares Underlying Options, Awarded | shares
Weighted Average Exercise Price, Awarded | $ / shares
Shares Underlying Options, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Shares Underlying Options, Expired | shares
Weighted Average Exercise Price, Expired | $ / shares
Shares Underlying Options, Outstanding Ending | shares	60,170
Weighted Average Exercise Price, Outstanding Ending | $ / shares	$ 171.23
Shares Underlying Options, Exercisable | shares	21,297
Weighted Average Exercise Price, Exercisable | $ / shares	$ 462.93

Share-based compensation, war_3

Share-based compensation, warrants and common stock issuances (Details Narrative) - USD ($)					3 Months Ended		12 Months Ended
	Feb. 21, 2024	Dec. 21, 2023	Dec. 18, 2023	May 17, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, shares issued				35,000	5,210,876		1,547,042
Warrant, down round feature, decrease in net income to common shareholder amount					$ 5,508,000
SeriesB1 And SeriesB2 Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Proceeds from issuance of warrants	$ 5,027,000
Warrant, down round feature, decrease in net income to common shareholder amount	481,000
SeriesB1 And SeriesB2 Warrant [Member] | Investor [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrant, down round feature, decrease in net income to common shareholder amount	$ 5,508,000
H.C. Wainright & Co., LLC [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants to purchase of common stock					146,667
Fair value of warrants					$ 100,000
December 2023 Public Offering [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price					$ 1.1563
Reduced exercise price			$ 1.875
Fair value of warrants							$ 154
December 2023 Public Offering [Member] | Convertible Note [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price		$ 1.50
Sale of stock, description of transaction		(i) 54,461 shares of Common Stock, (ii) the Private Pre-Funded Warrants to purchase up to 2,612,205 shares of common stock, (iii) the Series A Private Warrants to purchase up to 2,666,666 shares of common stock and (iv) the Series B Private Warrants to purchase up to 2,666,666 shares of common stock upon the exchange and cancellation of the $4,000 outstanding principal amount of the Convertible Note
Debt Instrument, Face Amount		$ 4,000,000
December 2023 Public Offering [Member] | H.C. Wainright & Co., LLC [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants to purchase of common stock			150,417
Securities Purchase Agreement [Member] | December 2023 Public Offering [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, shares issued			520,000
Proceeds from issuance of warrants			$ 3,900,000
Proceeds from exclusive of warrant issuance costs			100,000
Placement Agency Agreement [Member] | December 2023 Public Offering [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Cash fee			400,000
Legal and other fees			$ 600,000
February 2024 Warrant Exchange Agreement [Member] | Series B Common Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise of warrant	2,933,334
Reduced exercise price	$ 0.925
Increase exercise price	1.50
February 2024 Warrant Exchange Agreement [Member] | Series B-1 Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 0.74
Warrants to purchase of common stock	2,200,000
February 2024 Warrant Exchange Agreement [Member] | Series B-2 Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 0.74
Warrants to purchase of common stock	2,200,001
February 2024 Warrant Exchange Agreement [Member] | Series A Common Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 0.74
Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise of warrant					1,980,000
Common stock, shares issued				276,134	1,980,000
Shares issued price per, share				$ 12.675
Common Stock [Member] | Securities Purchase Agreement [Member] | December 2023 Public Offering [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares issued price per, share			$ 1.50
Common Stock [Member] | Securities Purchase Agreement [Member] | December 2023 Public Offering [Member] | Series A Common Stock Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, shares issued			3,333,334
Common Stock [Member] | Securities Purchase Agreement [Member] | December 2023 Public Offering [Member] | Series B Common Stock Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, shares issued			3,333,334
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrant purchase, shares				241,134
Shares price				$ 10.80
Warrant [Member] | Securities Purchase Agreement [Member] | December 2023 Public Offering [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrant purchase, shares			2,813,334
Prefunded Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, shares issued					2,432,705
Shares issued price per, share				$ 12.674
Proceeds from issuance of warrants				$ 3,000,000
Proceeds from inclusive of issuance costs				500,000
Proceeds from exclusive of warrant issuance costs				$ 200,000
Exercise price				$ 0.0001
Prefunded Warrant [Member] | December 2023 Public Offering [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price			$ 0.0001
Beneficially owned percentage of holder and affiliates			4.99%
Beneficially owned percentage			9.99%
Prefunded Warrant [Member] | December 2023 Public Offering [Member] | Series A Common Stock Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price			$ 1.50
Prefunded Warrant [Member] | December 2023 Public Offering [Member] | Series B Common Stock Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price			$ 1.50
Beneficially owned percentage of holder and affiliates			4.99%
Beneficially owned percentage			9.99%
Prefunded Warrant [Member] | Securities Purchase Agreement [Member] | December 2023 Public Offering [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares issued price per, share			$ 1.4999
Proceeds from inclusive of issuance costs			$ 1,100,000
Placement Agent Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrant purchase, shares					13,806
Exercise price					$ 15.845
Pre-Funded Warrants [Member] | December 2023 Public Offering [Member] | Convertible Note [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price		$ 0.0001
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average recognition period					6 months 14 days
Outstanding restricted stock unit awards					1,009		1,009
Weighted average grant date fair value					$ 125.42		$ 125.42
Unamortization stock compensation					$ 14,000
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock based compensation for stock options					$ 313,000
Weighted-average recognition period					1 year 1 month 17 days

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ in Thousands	May 13, 2024	Mar. 10, 2024
Subsequent Event [Line Items]
Potential cash bonus payments		$ 900,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Potential cash bonus payments	$ 900,000
Subsequent Event [Member] | Chief Executive Officer [Member]
Subsequent Event [Line Items]
Potential cash bonus payments	288,000
Subsequent Event [Member] | Chief Accounting Officer [Member]
Subsequent Event [Line Items]
Potential cash bonus payments	100,000
Subsequent Event [Member] | Remaining Employees [Member]
Subsequent Event [Line Items]
Potential cash bonus payments	$ 512,000